PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2760844-2	1989	Release was monitored by measuring endogenous ACh when acetylcholinesterase (AChE) was inhibited with physostigmine (30 microM) or by measuring endogenous choline when AChE activity was left intact.	Acetylcholine	46-49	acetylcholinesterase	Rattus norvegicus	77-81	
2760844-2	1989	Release was monitored by measuring endogenous ACh when acetylcholinesterase (AChE) was inhibited with physostigmine (30 microM) or by measuring endogenous choline when AChE activity was left intact.	Physostigmine	102-115	acetylcholinesterase	Rattus norvegicus	55-75	
2760844-2	1989	Release was monitored by measuring endogenous ACh when acetylcholinesterase (AChE) was inhibited with physostigmine (30 microM) or by measuring endogenous choline when AChE activity was left intact.	Physostigmine	102-115	acetylcholinesterase	Rattus norvegicus	77-81	
2760844-2	1989	Release was monitored by measuring endogenous ACh when acetylcholinesterase (AChE) was inhibited with physostigmine (30 microM) or by measuring endogenous choline when AChE activity was left intact.	Choline	61-68	acetylcholinesterase	Rattus norvegicus	77-81	
2760844-3	1989	The classical antagonist, atropine (0.1-2 microM), induced an increase in release whether AChE activity was inhibited or intact.	Atropine	26-34	acetylcholinesterase	Rattus norvegicus	90-94	
2760844-4	1989	The putative M-1 selective antagonist, pirenzepine, had minimal effects over a broad concentration range (2-200 microM) and induced an increase in ACh release only when AChE activity was inhibited.	Pirenzepine	39-50	acetylcholinesterase	Rattus norvegicus	169-173	
2760844-5	1989	The classical agonist, oxotremorine (10-100 microM) decreased effectively ACh release (by 22-35%), but only when AChE activity was intact.	Oxotremorine	23-35	acetylcholinesterase	Rattus norvegicus	113-117	
2760844-6	1989	The oxotremorine analog, oxotremorine-M, was apparently more potent than oxotremorine, but also decreased ACh release (by 24-41%) only when AChE activity was intact.	Oxotremorine	4-16	acetylcholinesterase	Rattus norvegicus	140-144	
2760844-6	1989	The oxotremorine analog, oxotremorine-M, was apparently more potent than oxotremorine, but also decreased ACh release (by 24-41%) only when AChE activity was intact.	Oxotremorine	25-37	acetylcholinesterase	Rattus norvegicus	140-144	
2760844-6	1989	The oxotremorine analog, oxotremorine-M, was apparently more potent than oxotremorine, but also decreased ACh release (by 24-41%) only when AChE activity was intact.	Oxotremorine	25-37	acetylcholinesterase	Rattus norvegicus	140-144	
2760844-7	1989	Another oxotremorine analog, BM-5, behaved more like a muscarinic antagonist in its effects on neostriatal ACh release, and the highest concentration tested (100 microM) increased release (by 47%) when AChE activity was left intact.	Oxotremorine	8-20	acetylcholinesterase	Rattus norvegicus	202-206	
2760844-7	1989	Another oxotremorine analog, BM-5, behaved more like a muscarinic antagonist in its effects on neostriatal ACh release, and the highest concentration tested (100 microM) increased release (by 47%) when AChE activity was left intact.	N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide	29-33	acetylcholinesterase	Rattus norvegicus	202-206